

Mutational Profile of Metastatic Breast Cancers: A Retro

PLoS Medicine

13, e1002201

DOI: [10.1371/journal.pmed.1002201](https://doi.org/10.1371/journal.pmed.1002201)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2630-2639.	3.2	30
2	Mutational Signatures in Breast Cancer: The Problem at the DNA Level. <i>Clinical Cancer Research</i> , 2017, 23, 2617-2629.	3.2	102
4	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 4402-4415.	3.2	91
5	Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2017, 28, 2866-2873.	0.6	67
6	Deconvolution of DNA methylation identifies differentially methylated gene regions on 1p36 across breast cancer subtypes. <i>Scientific Reports</i> , 2017, 7, 11594.	1.6	20
7	Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid. <i>ESMO Open</i> , 2017, 2, e000270.	2.0	15
8	p120-Catenin Downregulation and <i>PIK3CA</i> Mutations Cooperate to Induce Invasion through MMP1 in HNSCC. <i>Molecular Cancer Research</i> , 2017, 15, 1398-1409.	1.5	20
9	The SHIVA01 trial: what have we learned?. <i>Pharmacogenomics</i> , 2017, 18, 831-834.	0.6	4
10	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	11
11	The Role of PALB2 in the DNA Damage Response and Cancer Predisposition. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1886.	1.8	70
12	EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1172.	1.8	73
13	Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 567-579.	1.0	10
14	Risk Factors and Preventions of Breast Cancer. <i>International Journal of Biological Sciences</i> , 2017, 13, 1387-1397.	2.6	889
15	Analysis of <i>ESR1</i> and <i>PIK3CA</i> mutations in plasma cell-free DNA from ER-positive breast cancer patients. <i>Oncotarget</i> , 2017, 8, 52142-52155.	0.8	48
16	Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1. <i>Nature Communications</i> , 2018, 9, 967.	5.8	33
17	Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. <i>Annals of Oncology</i> , 2018, 29, 563-572.	0.6	135
18	Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes. <i>Oncology</i> , 2018, 94, 176-189.	0.9	20
19	Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2018, 29, 640-645.	0.6	245

#	ARTICLE	IF	CITATIONS
20	Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs). <i>BMC Cancer</i> , 2018, 18, 174.	1.1	22
21	Bridging the molecular and biological functions of the oxysterol-binding protein family. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 3079-3098.	2.4	76
23	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-553.	0.8	162
24	Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	1.5	43
25	Novel Agents for the Management of Endocrine Resistant Breast Cancer. <i>Current Breast Cancer Reports</i> , 2018, 10, 274-281.	0.5	0
26	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018, 9, 20617-20630.	0.8	36
27	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. <i>European Journal of Cancer</i> , 2018, 104, 21-31.	1.3	53
28	Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors. <i>Nature Communications</i> , 2018, 9, 4172.	5.8	56
29	G�n�mologie du cancer du sein appliqu�e aux traitements. <i>Revue Francophone Des Laboratoires</i> , 2018, 2018, 52-60.	0.0	0
30	A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	169
31	Structural snapshots of RAF kinase interactions. <i>Biochemical Society Transactions</i> , 2018, 46, 1393-1406.	1.6	28
32	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , 2018, 4, 34.	2.3	9
33	Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. <i>Journal of Cancer</i> , 2018, 9, 3640-3646.	1.2	19
34	Novel splicing in IGFN1 intron 15 and role of stable G-quadruplex in the regulation of splicing in renal cell carcinoma. <i>PLoS ONE</i> , 2018, 13, e0205660.	1.1	22
35	Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular stress. <i>Scientific Reports</i> , 2018, 8, 13904.	1.6	25
36	APOBEC3H Subcellular Localization Determinants Define Zipcode for Targeting HIV-1 for Restriction. <i>Molecular and Cellular Biology</i> , 2018, 38, .	1.1	16
37	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. <i>Cancer Discovery</i> , 2018, 8, 1390-1403.	7.7	397
38	Genetic Alterations of TRAF Proteins in Human Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 2111.	2.2	67

#	ARTICLE	IF	CITATIONS
39	APOBEC3B Nuclear Localization Requires Two Distinct N-Terminal Domain Surfaces. <i>Journal of Molecular Biology</i> , 2018, 430, 2695-2708.	2.0	42
40	Splicing dysregulation as a driver of breast cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R467-R478.	1.6	31
41	Clinical and molecular aspects of breast cancer: Targets and therapies. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 14-34.	2.5	49
42	Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein-Barr Virus (EBV). <i>Frontiers in Oncology</i> , 2018, 8, 1.	1.3	175
43	Precision Medicine in Hormone Receptor-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 144.	1.3	32
44	The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer. <i>Hormones and Cancer</i> , 2018, 9, 215-228.	4.9	36
45	Importance of genetic background of oxysterol signaling in cancer. <i>Biochimie</i> , 2018, 153, 109-138.	1.3	11
46	Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 88.	2.2	53
47	Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance. <i>Cancers</i> , 2018, 10, 274.	1.7	83
48	Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. <i>Nature Medicine</i> , 2018, 24, 724-730.	15.2	637
49	Breast cancer genome analysis in time and space: biomarker development strategy. <i>Biomarkers in Medicine</i> , 2018, 12, 547-550.	0.6	2
50	A Spontaneous Aggressive ER ⁺ Mammary Tumor Model Is Driven by Kras Activation. <i>Cell Reports</i> , 2019, 28, 1526-1537.e4.	2.9	19
51	Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases. <i>Nature Communications</i> , 2019, 10, 3190.	5.8	64
52	FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. <i>Npj Breast Cancer</i> , 2019, 5, 19.	2.3	46
53	Enhanced hexosamine metabolism drives metabolic and signaling networks involving hyaluronan production and O-GlcNAcylation to exacerbate breast cancer. <i>Cell Death and Disease</i> , 2019, 10, 803.	2.7	33
54	The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 188315.	3.3	28
55	Cancer: Context Is Key for E-cadherin in Invasion and Metastasis. <i>Current Biology</i> , 2019, 29, R1140-R1142.	1.8	8
56	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. <i>European Journal of Cancer</i> , 2019, 120, 54-64.	1.3	18

#	ARTICLE	IF	CITATIONS
57	Estrogen receptor 1 mutations in 260 cervical cancer samples from Chinese patients. <i>Oncology Letters</i> , 2019, 18, 2771-2776.	0.8	4
58	The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. <i>Nature Genetics</i> , 2019, 51, 1450-1458.	9.4	250
60	Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , 2019, 30, 365-373.	0.6	106
61	Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget's Diseases. <i>Journal of Investigative Dermatology</i> , 2019, 139, 789-795.	0.3	35
62	The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1. <i>Journal of Biological Chemistry</i> , 2019, 294, 12099-12111.	1.6	21
63	Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. <i>Cells</i> , 2019, 8, 605.	1.8	12
64	Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene. <i>PeerJ</i> , 2019, 7, e6501.	0.9	18
65	Estrogen therapy induces an unfolded protein response to drive cell death in ER + breast cancer. <i>Molecular Oncology</i> , 2019, 13, 1778-1794.	2.1	16
66	The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. <i>Cell Reports</i> , 2019, 27, 2690-2708.e10.	2.9	95
67	Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 116, 108997.	2.5	21
68	ESR1 mutations: a new biomarker in breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 599-611.	1.5	43
69	Genomic characterization of metastatic breast cancers. <i>Nature</i> , 2019, 569, 560-564.	13.7	448
70	Cytoplasmic HAX1 Is an Independent Risk Factor for Breast Cancer Metastasis. <i>Journal of Oncology</i> , 2019, 2019, 1-13.	0.6	8
71	An analysis of available biomarker data for targeting cyclin-dependent kinases 4 and 6 (CDK4/6) in breast cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 129-138.	0.4	1
72	Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data. <i>Nature Communications</i> , 2019, 10, 2138.	5.8	58
73	Genomic Profiling of the Steroidogenic Acute Regulatory Protein in Breast Cancer: In Silico Assessments and a Mechanistic Perspective. <i>Cancers</i> , 2019, 11, 623.	1.7	10
74	Cancer Treatment in the Genomic Era. <i>Annual Review of Biochemistry</i> , 2019, 88, 247-280.	5.0	24
75	Network Pharmacology Analysis of <i>Damnacanthus indicus</i> C.F.Gaertn in Gene-Phenotype. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-9.	0.5	7

#	ARTICLE	IF	CITATIONS
76	Integrating of genomic and transcriptomic profiles for the prognostic assessment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 691-699.	1.1	11
77	Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. <i>Cancers</i> , 2019, 11, 441.	1.7	3
78	Nuclear Receptor Coactivator 2 Promotes Human Breast Cancer Cell Growth by Positively Regulating the MAPK/ERK Pathway. <i>Frontiers in Oncology</i> , 2019, 9, 164.	1.3	18
79	Genomics applied to the treatment of breast cancer. <i>Oncotarget</i> , 2019, 10, 4786-4801.	0.8	20
80	Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics. <i>Medicine (United States)</i> , 2019, 98, e16702.	0.4	2
81	Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. <i>Molecular Cancer Research</i> , 2019, 17, 97-108.	1.5	17
82	Genomic Applications in Breast Carcinoma. , 2019, , 347-361.		0
83	Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. <i>Clinical Breast Cancer</i> , 2019, 19, 113-125.e4.	1.1	8
84	Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. <i>Medicinal Research Reviews</i> , 2019, 39, 1205-1227.	5.0	21
85	Novel Biomarkers Predicting the Development of Bone Metastasis in Early Breast Cancer. , 2019, , 363-370.		0
86	Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions. <i>Annals of Diagnostic Pathology</i> , 2019, 39, 30-35.	0.6	9
87	Molecular Mechanisms of Endocrine Resistance. <i>Cancer Drug Discovery and Development</i> , 2019, , 265-307.	0.2	5
88	Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. <i>Nature Genetics</i> , 2019, 51, 207-216.	9.4	170
89	Activated kinase screening identifies the <i>IKBKE</i> oncogene as a positive regulator of autophagy. <i>Autophagy</i> , 2019, 15, 312-326.	4.3	25
90	TTF-1-positive Metastatic Endometrioid Carcinoma: A Case Report and Review of Literature of a Potential Diagnostic Pitfall. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, e6-e9.	0.6	4
91	Know your enemy: Genetics, aging, exposomic and inflammation in the war against triple negative breast cancer. <i>Seminars in Cancer Biology</i> , 2020, 60, 285-293.	4.3	16
92	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , 2020, 14, 504-519.	2.1	23
93	A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2 ⁻ Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e232-e243.	1.1	29

#	ARTICLE	IF	CITATIONS
94	8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3079.	1.0	16
95	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 53.	2.3	27
96	Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions. <i>BMC Cancer</i> , 2020, 20, 944.	1.1	9
97	The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives. <i>Cancers</i> , 2020, 12, 3029.	1.7	54
98	Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. <i>Genome Medicine</i> , 2020, 12, 85.	3.6	39
99	Identifying Genomic Alterations in Patients With Stage IV Breast Cancer Using MammaSeq: An International Collaborative Study. <i>Clinical Breast Cancer</i> , 2021, 21, 210-217.	1.1	4
100	Currently Applied Molecular Assays for Identifying ESR1 Mutations in Patients with Advanced Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8807.	1.8	6
101	APOBEC3A catalyzes mutation and drives carcinogenesis in vivo. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	87
102	Bioinformatic analysis reveals the molecular targets of tangeretin in overcoming the resistance of breast cancer to tamoxifen. <i>Gene Reports</i> , 2020, 21, 100884.	0.4	2
103	FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis. <i>International Journal of Medical Sciences</i> , 2020, 17, 2819-2825.	1.1	3
104	A meta-analysis of BRF2 as a prognostic biomarker in invasive breast carcinoma. <i>BMC Cancer</i> , 2020, 20, 1093.	1.1	11
105	Innovative Options for Bone Metastasis Treatment: An Extensive Analysis on Biomaterials-Based Strategies for Orthopedic Surgeons. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 589964.	2.0	18
106	A Bioinformatic Pipeline Places STAT5A as a miR-650 Target in Poorly Differentiated Aggressive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7720.	1.8	1
107	Identification of novel molecular markers of mastitis caused by <i>Staphylococcus aureus</i> using gene expression profiling in two consecutive generations of Chinese Holstein dairy cattle. <i>Journal of Animal Science and Biotechnology</i> , 2020, 11, 98.	2.1	26
108	Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor. <i>Nature Communications</i> , 2020, 11, 4875.	5.8	24
109	Clinical implications of prospective genomic profiling of metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2020, 22, 91.	2.2	32
110	Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?. <i>Current Oncology Reports</i> , 2020, 22, 57.	1.8	26
111	Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China. <i>Cancer Communications</i> , 2020, 40, 260-269.	3.7	18

#	ARTICLE	IF	CITATIONS
112	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 45.	2.2	175
113	The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. <i>PLoS ONE</i> , 2020, 15, e0231999.	1.1	36
114	Effects of estrogen receptor signaling on prostate cancer carcinogenesis. <i>Translational Research</i> , 2020, 222, 56-66.	2.2	7
115	Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA. <i>Thoracic Cancer</i> , 2020, 11, 1861-1868.	0.8	8
116	Regulation of breast cancer metastasis signaling by miRNAs. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 837-886.	2.7	87
117	Acquisition of chromosome instability is a mechanism to evade oncogene addiction. <i>EMBO Molecular Medicine</i> , 2020, 12, e10941.	3.3	45
118	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 18.	1.3	72
119	The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers. <i>Cancer Research</i> , 2020, 80, 3062-3069.	0.4	8
120	A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2â€“ Metastatic Breast Cancer. <i>International Journal of Breast Cancer</i> , 2020, 2020, 1-16.	0.6	33
121	Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate. <i>Scientific Reports</i> , 2020, 10, 1852.	1.6	65
122	Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 7-22.	0.4	5
123	Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system. <i>Oncolmmunology</i> , 2020, 9, 1724049.	2.1	12
124	Embryonic Barcoding of Equipotent Mammary Progenitors Functionally Identifies Breast Cancer Drivers. <i>Cell Stem Cell</i> , 2020, 26, 403-419.e4.	5.2	15
125	Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, 377-386.	0.6	173
126	Integrated analysis of gene expression, alteration and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 1 in cancer. <i>3 Biotech</i> , 2020, 10, 132.	1.1	3
127	Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group. <i>Cancer Genetics</i> , 2020, 244, 11-20.	0.2	4
128	Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 331-341.	1.1	17
129	Precision in cancer pharmacogenomics. <i>Pharmacogenomics</i> , 2020, 21, 311-316.	0.6	1

#	ARTICLE	IF	CITATIONS
130	Expression pattern, regulation, and clinical significance of TOX in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 349-363.	2.0	13
131	Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial. <i>Molecular Oncology</i> , 2021, 15, 104-115.	2.1	10
132	Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. <i>Cell Research</i> , 2021, 31, 178-186.	5.7	146
133	Insulin-Induced Gene 2 Expression Is Associated with Breast Cancer Metastasis. <i>American Journal of Pathology</i> , 2021, 191, 385-395.	1.9	2
134	Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1105-1118.	3.2	24
135	The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters. <i>Breast Journal</i> , 2021, 27, 104-104.	0.4	0
136	Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 27-32.	1.5	2
137	Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. <i>Oncogene</i> , 2021, 40, 1318-1331.	2.6	10
138	Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy. <i>Journal of Translational Medicine</i> , 2021, 19, 7.	1.8	0
139	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. <i>Genes</i> , 2021, 12, 285.	1.0	18
140	Worm-Based Microfluidic Biosensor for Real-Time Assessment of the Metastatic Status. <i>Cancers</i> , 2021, 13, 873.	1.7	13
141	Up-regulation of oxysterol-binding protein 3 in lung tissue of patients with non-small lung cancer. <i>Gene Reports</i> , 2021, 22, 100998.	0.4	0
142	Distinct Somatic Alteration Features Identified by Gene Panel Sequencing in Korean Triple-Negative Breast Cancer with High Ki67 Expression. <i>Diagnostics</i> , 2021, 11, 416.	1.3	0
143	PIK3CA Mutation Assessment in HR+/HER2 ⁻ Metastatic Breast Cancer: Overview for Oncology Clinical Practice. <i>Journal of Molecular Pathology</i> , 2021, 2, 42-54.	0.5	9
144	Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. <i>Genome Medicine</i> , 2021, 13, 44.	3.6	13
145	TRPS1 drives heterochromatic origin refiring and cancer genome evolution. <i>Cell Reports</i> , 2021, 34, 108814.	2.9	13
146	Genomic profile of advanced breast cancer in circulating tumour DNA. <i>Nature Communications</i> , 2021, 12, 2423.	5.8	54
147	Comprehensive omic characterization of breast cancer in Mexican-Hispanic women. <i>Nature Communications</i> , 2021, 12, 2245.	5.8	14

#	ARTICLE	IF	CITATIONS
148	Exploration of targets and molecular mechanisms of cinnamaldehyde in overcoming fulvestrant-resistant breast cancer: a bioinformatics study. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2021, 10, 1.	1.2	2
149	Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1559-1570.	1.5	6
150	Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). <i>Genetics in Medicine</i> , 2021, 23, 1416-1423.	1.1	34
151	Novel mutations in FSIP2 lead to multiple morphological abnormalities of the sperm flagella and poor ICSI prognosis. <i>Gene</i> , 2021, 781, 145536.	1.0	20
152	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 683-693.	1.2	5
153	EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer. <i>BMC Medical Genomics</i> , 2021, 14, 122.	0.7	12
155	Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. <i>Cancer Medicine</i> , 2021, 10, 5163-5174.	1.3	11
156	Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 465-476.	1.1	1
157	Gene expression profiles of breast cancer metastasis according to organ site. <i>Molecular Oncology</i> , 2022, 16, 69-87.	2.1	24
158	Functional Genomic Analysis of Breast Cancer Metastasis: Implications for Diagnosis and Therapy. <i>Cancers</i> , 2021, 13, 3276.	1.7	6
159	Analyzing the influence of <i>IL18</i> in regulation of <i>YAP1</i> in breast oncogenesis using <i>bioportal</i> . <i>Cancer Reports</i> , 2022, 5, e1484.	0.6	2
160	Updates in the management of relapsed/refractory multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1477-1490.	0.5	2
161	Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. <i>Nature Cancer</i> , 2021, 2, 680-692.	5.7	56
162	Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-15.	0.5	7
163	Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites. <i>Npj Breast Cancer</i> , 2021, 7, 93.	2.3	17
164	De novo and cell line models of human mammary cell transformation reveal an essential role for Yb-1 in multiple stages of human breast cancer. <i>Cell Death and Differentiation</i> , 2021, , .	5.0	2
165	Mutational signatures: emerging concepts, caveats and clinical applications. <i>Nature Reviews Cancer</i> , 2021, 21, 619-637.	12.8	128
166	Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time. <i>Case Reports in Oncology</i> , 2021, 14, 1212-1219.	0.3	1

#	ARTICLE	IF	CITATIONS
167	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
168	Identification of putative actionable alterations in clinically relevant genes in breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1270-1284.	2.9	1
169	Combination of 35-Gene Mutation Profile and Radiotherapy Dosimetry Predicts the Therapeutic Outcome of Definitive Chemoradiation in Patients With Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 729418.	1.3	0
170	Identification and Prognostic Value Exploration of Radiotherapy Sensitivity-Associated Genes in Non-Small-Cell Lung Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-14.	0.9	6
171	Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 241-253.	1.1	8
172	Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 710596.	1.3	5
173	Dissecting the biological heterogeneity of HER2-positive breast cancer. <i>Breast</i> , 2021, 59, 339-350.	0.9	41
174	MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours. <i>Cancer Letters</i> , 2021, 519, 226-236.	3.2	10
175	FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188595.	3.3	13
176	Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and in vitro studies. <i>Saudi Pharmaceutical Journal</i> , 2021, 29, 12-26.	1.2	26
177	CDK4/6 inhibitors: a brief overview and prospective research directions. <i>RSC Advances</i> , 2021, 11, 29227-29246.	1.7	28
178	PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma. <i>Oncology Letters</i> , 2021, 21, 224.	0.8	6
179	Prune-1 drives polarization of tumor-associated macrophages (TAMs) within the lung metastatic niche in triple-negative breast cancer. <i>IScience</i> , 2021, 24, 101938.	1.9	11
180	Therapeutic Options for Metastatic Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 131-172.	0.8	20
181	Review ctDNA and Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020, 215, 231-252.	1.8	16
183	An Integrated Approach for Preventing Oral Cavity and Oropharyngeal Cancers: Two Etiologies with Distinct and Shared Mechanisms of Carcinogenesis. <i>Cancer Prevention Research</i> , 2020, 13, 649-660.	0.7	13
184	Mutational profiles of breast cancer metastases from a rapid autopsy series reveal multiple evolutionary trajectories. <i>JCI Insight</i> , 2017, 2, .	2.3	19
185	Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. <i>Journal of Clinical Investigation</i> , 2020, 130, 4252-4265.	3.9	61

#	ARTICLE	IF	CITATIONS
186	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 4871-4887.	3.9	49
187	ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. <i>Breast Cancer Research</i> , 2020, 22, 16.	2.2	56
189	The INO80 chromatin remodeler sustains metabolic stability by promoting TOR signaling and regulating histone acetylation. <i>PLoS Genetics</i> , 2018, 14, e1007216.	1.5	23
190	A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy. <i>Oncotarget</i> , 2017, 8, 103327-103339.	0.8	5
191	<i>GATA3</i> frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary <i>GATA3</i> mutant breast cancers. <i>Oncotarget</i> , 2017, 8, 103415-103427.	0.8	28
192	The phosphorylation status of PIP5K1C at serine 448 can be predictive for invasive ductal carcinoma of the breast. <i>Oncotarget</i> , 2018, 9, 36358-36370.	0.8	6
193	Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. <i>Annals of Translational Medicine</i> , 2019, 7, 179-179.	0.7	56
194	Circulating tumor cells and breast cancer-specific mutations in primary breast cancer. <i>Molecular and Clinical Oncology</i> , 2020, 12, 565-573.	0.4	4
195	ZW10 interacting kinetochore protein may serve as a prognostic biomarker for human breast cancer: An integrated bioinformatics analysis. <i>Oncology Letters</i> , 2020, 19, 2163-2174.	0.8	12
196	The Evolution of Clinically Aggressive Triple-Negative Breast Cancer Shows a Large Mutational Diversity and Early Metastasis to Lymph Nodes. <i>Cancers</i> , 2021, 13, 5091.	1.7	4
197	ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. <i>British Journal of Cancer</i> , 2022, 126, 174-186.	2.9	37
198	Biomarkers of immunotherapy response in breast cancer beyond PD-L1. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 39-49.	1.1	11
204	Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. <i>Cancers</i> , 2021, 13, 5416.	1.7	7
205	SMARCA4 Depletion Induces Cisplatin Resistance by Activating YAP1-Mediated Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 5474.	1.7	15
206	Personalized Management of Cancers of Various Organs/Systems. , 2021, , 509-602.		0
207	Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing. <i>Theranostics</i> , 2021, 11, 9967-9987.	4.6	6
209	Clinical Value and Potential Mechanisms of Oxysterol-Binding Protein Like 3 (OSBPL3) in Human Tumors. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 739978.	1.6	5
210	Discovery of a novel potentially transforming somatic mutation in <i>CSF2RB</i> gene in breast cancer. <i>Cancer Medicine</i> , 2021, 10, 8138-8150.	1.3	6

#	ARTICLE	IF	CITATIONS
211	Identification of potential gene associated with berberine in overcoming tamoxifen resistance by functional network analysis. <i>Journal of Applied Pharmaceutical Science</i> , 0, , .	0.7	1
212	Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer: experiences from a case series. <i>Oncotarget</i> , 2020, 11, 3279-3285.	0.8	2
213	Mutational landscape implicates epithelial-mesenchymal transition gene TGF- β 2 mutations for uterine carcinosarcoma after adjuvant tamoxifen therapy for breast carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 996-1002.	0.5	0
214	Integrative Bioinformatics Analysis Reveals Potential Target Genes and TNF α Signaling Inhibition by Brazilin in Metastatic Breast Cancer Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 2751-2762.	0.5	1
215	First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study. <i>Clinical Cancer Research</i> , 2022, 28, 618-628.	3.2	25
216	ZHX2 promotes HIF1 α oncogenic signaling in triple-negative breast cancer. <i>ELife</i> , 2021, 10, .	2.8	21
217	Genomic characterization of de novo metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	1
219	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. <i>Nature Communications</i> , 2021, 12, 7033.	5.8	27
220	Integrative Bioinformatics Analysis Reveals Potential Target Genes and TNF α Signaling Inhibition by Brazilin in Metastatic Breast Cancer Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 2751-2762.	0.5	7
221	Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer. <i>Cancers</i> , 2021, 13, 6314.	1.7	3
222	Cohesin in DNA damage response and double-strand break repair. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2022, 57, 333-350.	2.3	5
224	Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. <i>Cancers</i> , 2022, 14, 1151.	1.7	5
225	Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience. <i>Current Issues in Molecular Biology</i> , 2022, 44, 1332-1352.	1.0	4
226	A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets. <i>Frontiers in Oncology</i> , 2022, 12, 786438.	1.3	6
227	MCL-1 is a clinically targetable vulnerability in breast cancer. <i>Cell Cycle</i> , 2022, 21, 1439-1455.	1.3	10
228	Clinical Impact of 11q13.3 Amplification on Immune Cell Infiltration and Prognosis in Breast Cancer. <i>International Journal of General Medicine</i> , 2022, Volume 15, 4037-4052.	0.8	4
229	Functional network analysis of p85 and PI3K as potential gene targets and mechanism of oleanolic acid in overcoming breast cancer resistance to tamoxifen. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 66.	1.5	3
230	Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 62.	2.3	10

#	ARTICLE	IF	CITATIONS
231	Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.. American Journal of Cancer Research, 2022, 12, 1784-1823.	1.4	0
232	Dietary phytochemicals/nutrients as promising protector of breast cancer development: a comprehensive analysis. Pharmacological Reports, 0, , .	1.5	4
233	APOBEC3: Friend or Foe in Human Papillomavirus Infection and Oncogenesis?. Annual Review of Virology, 2022, 9, 375-395.	3.0	11
234	Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. Frontiers in Oncology, 0, 12, .	1.3	22
235	ECM1 is associated with endocrine resistance in ER⁺ breast cancers. Animal Cells and Systems, 2022, 26, 99-107.	0.8	3
236	Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. Npj Breast Cancer, 2022, 8, .	2.3	8
237	A Novel Artificial Neural Network Prognostic Model Based on a Cancer-Associated Fibroblast Activation Score System in Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	4
238	Emerging Trends in Bioinformatics for Breast Cancer Molecular Research. , 2022, , 86-108.		0
239	MDM2 is a Potential Target Gene of Glycyrrhizic Acid for Circumventing Breast Cancer Resistance to Tamoxifen: Integrative Bioinformatics Analysis. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2341-2350.	0.5	3
240	Prevalence of Estrogen Receptor Alpha (<i>ESR1</i>) Somatic Mutations in Breast Cancer. JNCI Cancer Spectrum, 0, , .	1.4	0
241	Rare germline <i>ATM</i> variants of uncertain significance in chronic lymphocytic leukaemia and other cancers. British Journal of Haematology, 0, , .	1.2	1
242	HMOX1 promotes lung adenocarcinoma metastasis by affecting macrophages and mitochondrion complexes. Frontiers in Oncology, 0, 12, .	1.3	4
243	Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets. BMC Cancer, 2022, 22, .	1.1	1
244	Plasma exosomal IRAK1 can be a potential biomarker for predicting the treatment response to renin-angiotensin system inhibitors in patients with IgA nephropathy. Frontiers in Immunology, 0, 13, .	2.2	0
245	Breast cancer metastasis: Is it a matter of OMICS and proper ex-vivo models?. Computational and Structural Biotechnology Journal, 2022, 20, 4003-4008.	1.9	4
246	Synthetic-Based Tumor-Infiltrating Lymphocytes (TILs) in Adoptive Cell Therapies. , 2022, , 1-27.		0
247	The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets. Genes, 2022, 13, 1555.	1.0	2
248	S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer. Molecular Cancer, 2022, 21, .	7.9	13

#	ARTICLE	IF	CITATIONS
249	ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. <i>Cell Reports</i> , 2022, 40, 111268.	2.9	5
252	Somatic Mutations of <i>TP53</i> Identified by Targeted Next-Generation Sequencing Are Poor Prognostic Factors for Primary Operable Breast Cancer: A Single-Center Study. <i>Journal of Breast Cancer</i> , 2022, 25, 379.	0.8	5
253	Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. <i>Current Oncology Reports</i> , 2022, 24, 1801-1819.	1.8	7
254	The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets. <i>Cancers</i> , 2022, 14, 5306.	1.7	12
255	Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2023, 112, 102496.	3.4	18
256	SETD7 Expression Is Associated with Breast Cancer Survival Outcomes for Specific Molecular Subtypes: A Systematic Analysis of Publicly Available Datasets. <i>Cancers</i> , 2022, 14, 6029.	1.7	2
257	Identification of potential target genes of honokiol in overcoming breast cancer resistance to tamoxifen. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
258	ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). <i>PLoS Genetics</i> , 2023, 19, e1010563.	1.5	5
259	ESR1 Mutations as a Predictor of Progression and Metastasis of Hormone-Dependent Breast Cancer. <i>Ukrainskij Zhurnal Medicini Biologicheskogo Ta Sportu</i> , 2022, 7, 6-15.	0.0	0
260	Deciphering gene contributions and etiologies of somatic mutational signatures of cancer. <i>Briefings in Bioinformatics</i> , 2023, 24, .	3.2	0
261	Whole Exome Sequencing Study Suggests an Impact of FANCA, CDH1 and VEGFA Genes on Diffuse Gastric Cancer Development. <i>Genes</i> , 2023, 14, 280.	1.0	2
262	Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer. <i>Diagnostics</i> , 2023, 13, 470.	1.3	1
264	Introduction to Breast Cancer. , 2023, , 1-22.		1
265	AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	3
266	Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors. <i>Neoplasia</i> , 2023, 38, 100888.	2.3	2
267	The RUNX/CBF β Complex in Breast Cancer: A Conundrum of Context. <i>Cells</i> , 2023, 12, 641.	1.8	2
268	Bone marrow adipocytes induce cancer-associated fibroblasts and immune evasion, enhancing invasion and drug resistance. <i>Cancer Science</i> , 2023, 114, 2674-2688.	1.7	7
269	<i>PIK3CA</i> copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer. <i>Journal of Physical Education and Sports Management</i> , 2023, 9, a006255.	0.5	3

#	ARTICLE	IF	CITATIONS
270	Performance of a <sc>PLK1</sc>-based immune risk model for prognosis and treatment response prediction in breast cancer. Cancer Medicine, 0, , .	1.3	1
271	N-acetylcysteine overcomes NF1 loss-driven resistance to PI3K \uparrow inhibition in breast cancer. Cell Reports Medicine, 2023, 4, 101002.	3.3	3
288	New Directions in Systems Biology-based Target Identification and Cancer Genome Analysis. , 2023, , 52-80.		0